Competition will get severe between Viread and Baraclude
Expected to be applied for the insurance benefit on the solo therapy for multiple drug resistant patients, the Gilead’s hepatitis type B treatment, Viread (tenofovir), has kept its increasing curve.
It is expected that the product not only exceeded KRW 100 billion prescription expenses, meaning ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
